Teladoc Health (NYSE:TDOC) Announces FY 2026 Earnings Guidance

Posted by George Bondi on Oct 30th, 2026

Teladoc Health (NYSE:TDOC – Get Free Report) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of -0.950–0.750 for the period, compared to the consensus EPS estimate of -0.810. The company issued revenue guidance of $2.4 billion, compared to the consensus revenue estimate of $2.4 billion. Teladoc Health also updated its Q4 2026 guidance to -0.230–0.030 EPS.

Analyst Ratings Changes

A number of brokerages have issued reports on TDOC. Canaccord Genuity Group dropped their target price on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Citigroup lowered their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Stifel Nicolaus upped their price objective on Teladoc Health from $5.50 to $6.50 and gave the company a “hold” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Finally, Bank of America raised their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.54.

Check Out Our Latest Research Report on TDOC

Teladoc Health Price Performance

NYSE TDOC opened at $8.88 on Friday. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89. The firm has a market capitalization of $1.61 billion, a P/E ratio of -10.32 and a beta of 2.14. The business’s 50-day simple moving average is $6.19 and its 200-day simple moving average is $6.47.

Teladoc Health (NYSE:TDOC – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The firm had revenue of $605.10 million for the quarter, compared to analysts’ expectations of $588.14 million. During the same period in the previous year, the company posted ($0.28) earnings per share. Teladoc Health’s revenue was down 3.4% compared to the same quarter last year. On average, equities research analysts expect that Teladoc Health will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the sale, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by insiders.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, ahead of the approximately $588 million consensus estimate, while its $0.15 per-share loss was narrower than the expected $0.22 loss. Revenue still declined about 3% year over year, but the results exceeded expectations. Teladoc Health Reports Third Quarter 2026 Results
Positive Sentiment: Adjusted EBITDA reached approximately $79 million, near the high end of management’s prior outlook, and cash-flow improvement made the quarterly loss appear higher quality to investors. Teladoc Health Stock Rebounds on Q3 Results as Cash Flow Improves
Positive Sentiment: BetterHelp generated $32 million of insurance revenue in the quarter. Management also highlighted a target insurance-related run rate of at least $200 million, supporting hopes that the mental-health business can diversify beyond direct consumer payments. Teladoc: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: The company plans to repurchase convertible notes, which could reduce debt-related obligations and signal confidence in its balance-sheet position. Teladoc Targets BetterHelp Insurance Run Rate and Plans Note Repurchase
Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average likely amplified the rally, but these are trading signals rather than changes to the company’s fundamentals.
Negative Sentiment: Fourth-quarter revenue guidance of $569 million to $615 million has a midpoint below the $601.7 million consensus estimate. Full-year 2026 EPS guidance of a $0.75 to $0.95 loss also brackets the consensus estimate of a $0.81 loss, underscoring that Teladoc remains unprofitable and growth remains pressured.
Negative Sentiment: Analyst support remains cautious: Stifel raised its price target to $6.50 but maintained a “hold” rating, implying substantial downside from the recent trading level.

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.